The renin-angiotensin and the kallikrein-kinin systems

被引:106
作者
Campbell, DJ
机构
[1] St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia
[2] Univ Melbourne, Dept Med, Fitzroy, Vic 3065, Australia
关键词
angiotensin; bradykinin; kallidin; kallikrein; kininogen; kallistatin;
D O I
10.1016/S1357-2725(02)00262-5
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The renin-angiotensin system (RAS) and the kallikrein-kinin system (KKS) each encompasses a large number of molecules, with several participating in both systems. The RAS generates a family of bioactive angiotensin peptides with varying biological activities. These include angiotensin-(1-8) (An-II), angiotensin-(2-8) (Ang III), angiotensin-(3-8) (Ang IV), and angiotensin-(1-7) [Ang-(1 -7)]. An-II and Ang III act on type 1 (AT(1)) and type 2 (AT(2)) angiotensin receptors, whereas, Ang IV and Ang-(1-7) act on their own receptors. The KKS also generates a family of bioactive peptides with varying biological activities. These include hydroxylated and non-hydroxylated bradykinin and kallidin peptides and their carboxypeptidase metabolites des-Arg(9)-bradykinin and des-Arg(10)-kallidin. Whereas bradykinin and kallidin act mainly viathe type 2 bradykinin (B-2) receptor, des-Arg(9)-bradykinin and des-Arg(10)-kallidin act mainly via the type 1 bradykinin (B-1) receptor. The AT(1) receptor forms heterodimers with the AT(2) and B-2 receptors and there is cross talk between the AT(1) and epidermal growth factor receptors. The B-2 receptor also interacts with angiotensin converting enzyme and nitric oxide synthase. Both angiotensin and kinin peptides are metabolised by many different peptidases that are important determinants of the activities of the RAS and KKS, and several of which participate in both systems. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:784 / 791
页数:8
相关论文
共 32 条
[21]   High-molecular-weight kininogen is a binding protein for tissue prokallikrein [J].
Raab, A ;
Kemme, M .
FEBS LETTERS, 2000, 467 (2-3) :165-168
[22]   EFFECT OF INHIBITION OF ENDOPEPTIDASE 24.11 ON RESPONSES TO ANGIOTENSIN-II IN HUMAN VOLUNTEERS [J].
RICHARDS, AM ;
WITTERT, GA ;
ESPINER, EA ;
YANDLE, TG ;
IKRAM, H ;
FRAMPTON, C .
CIRCULATION RESEARCH, 1992, 71 (06) :1501-1507
[23]   PLASMA KALLIKREIN AND PLASMIN AS ACTIVATORS OF PRORENIN - LINKS BETWEEN THE RENIN-ANGIOTENSIN SYSTEM AND OTHER PROTEOLYTIC SYSTEMS IN PLASMA [J].
SCHALEKAMP, MADH ;
DERKX, FHM .
CLINICAL SCIENCE, 1981, 61 (01) :15-21
[24]   Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions [J].
Schmaier, AH .
CURRENT OPINION IN HEMATOLOGY, 2000, 7 (05) :261-265
[25]   Expression of kininogen mRNAs and plasma kallikrein mRNA by cultured neurons, astrocytes and meningeal cells in the rat brain [J].
Takano, M ;
Horie, M ;
Narahara, M ;
Miyake, M ;
Okamoto, H .
IMMUNOPHARMACOLOGY, 1999, 45 (1-3) :121-126
[26]   Regulation of angiotensin II type 1 (AT1) receptor function [J].
Thomas, WG .
REGULATORY PEPTIDES, 1999, 79 (01) :9-23
[27]   Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor [J].
Thomas, WG ;
Brandenburger, Y ;
Autelitano, DJ ;
Pham, T ;
Qian, HW ;
Hannan, RD .
CIRCULATION RESEARCH, 2002, 90 (02) :135-142
[28]   A human homolog of angiotensin-converting enzyme - Cloning and functional expression as a captopril-insensitive carboxypeptidase [J].
Tipnis, SR ;
Hooper, NM ;
Hyde, R ;
Karran, E ;
Christie, G ;
Turner, AJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (43) :33238-33243
[29]   Cardiovascular phenotypes of kinin B2 receptor- and tissue kallikrein-deficient mice [J].
Trabold, F ;
Pons, S ;
Hagege, AA ;
Bloch-Faure, M ;
Alhenc-Gelas, F ;
Giudicelli, JF ;
Richer-Giudicelli, C ;
Meneton, P .
HYPERTENSION, 2002, 40 (01) :90-95
[30]   Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes [J].
Tsuchida, S ;
Matsusaka, T ;
Chen, XM ;
Okubo, S ;
Niimura, F ;
Nishimura, H ;
Fogo, A ;
Utsunomiya, H ;
Inagami, T ;
Ichikawa, L .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (04) :755-760